UBS Starts Genzyme (GENZ) at Buy
More News related to GENZ
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
- Genzyme (GENZ) and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics
- Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
- Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
- National Notary Association Becomes Member of SAFE-BioPharma Association
More News related to New Coverage
- Morgan Stanley Resumes Coverage of Covidien (COV), Baxter (BAX), Becton Dickinson (BDX), Hospira (HSP), Integra (IART)
- Morgan Stanley Starts Waters Corp. (WAT) at Overweight
- Morgan Stanley Starts Illumina (ILMN) at Overweight
- Morgan Stanley Resumes Abbott Labs (ABT) at Overweight
- Sidoti Starts LaBarge (LB) at Buy
UBS initiates coverage on Genzyme Corp. (Nasdaq: GENZ) with a Buy rating.
Genzyme Corporation operates as a biotechnology company worldwide. It operates through five segments: Renal, Therapeutics, Transplant, Biosurgery, and Genetics.
Related Categories
New CoverageStocks Mentioned
-3.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
